• Affimed, formerly Affimed Therapeutics, a subsidiary of Affimed NV, discovers and develops immunotherapies to treat hematologic cancers and solid tumors. (pharmaceutical-technology.com)
  • Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
  • It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. (lookformedical.com)
  • To optimize their currently limited efficacy in solid tumors, increased understanding of their pharmacokinetics and in vivo internalization is needed. (bvsalud.org)
  • While CAR-T cell therapy has demonstrated a significant clinical effect against malignant blood tumors, TCR-T cell therapies have been tested in hematological and solid tumors. (cip.com.cn)
  • Among the 15 approved ADC drugs, 7 are for the treatment of hematological tumors and 8 are for the treatment of solid tumors. (huatengsci.com)
  • However, targeting solid tumors is more challenging than targeting B-cell malignancies with CAR-T cells because of the histopathological structure features, specific antigens shortage and strong immunosuppressive environment of solid tumors. (ijbs.com)
  • Optimization of the design of CAR vectors, exploration of new targets, addition of safe switches and combination with other treatments bring new vitality to the CAR-T cell based immunotherapy against solid tumors. (ijbs.com)
  • In this review, we focus on the major obstacles limiting the application of CAR-T cell therapy toward solid tumors and summarize the measures to refine this new cancer therapeutic modality. (ijbs.com)
  • Nevertheless, targeting solid tumors is more challenging than targeting hematological malignancies because of tumor histopathological characteristics, shortage of specific antigens and local strong immunosuppressive microenvironment [ 4 ]. (ijbs.com)
  • And much work remains to be done to improve the efficacy of CAR-T cell therapy for solid tumors. (ijbs.com)
  • It may be achieved, at least partially, by more extensive basic studies investigating the spatiotemporal dynamics of T cell activation by CARs and unraveling the connection between T cell migration in solid tumors and the effectiveness in eradication of solid tumors and metastases [ 5 ]. (ijbs.com)
  • In this review, we discuss the current status and major obstacles for the treatment of solid tumors with CAR-T cells, thus provide some potential measures to refine this novel therapeutic modality. (ijbs.com)
  • Helft PR, Schilsky RL, Hoke FJ et al (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. (springer.com)
  • The weak CD30 expression can aid in differentiating PMBCL from anaplastic large cell lymphoma and classic Hodgkin lymphoma. (medscape.com)
  • Coexpression of CD15 and CD30 (usually associated with classical Hodgkin's lymphoma) may be seen in some PTCL, NOS. (webpathology.com)
  • The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
  • 1 The most frequent primary tumor types of anterior mediastinal masses are thymic tumors and lymphoma, with approximate proportions of 35% and 25% among mediastinal lesions, respectively. (allenpress.com)
  • Anaplastic lymphoma of the skin which develops as a primary neoplasm expressing the CD30 ANTIGEN . (nih.gov)
  • B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. (lookformedical.com)
  • Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. (lookformedical.com)
  • Anaplastic large cell lymphoma with anaplastic lymphoma kinase gene translocations (ALK+ ALCL) is a mature T-cell lymphoma that primarily affects lymph nodes, but also gives rise to tumors in extranodal organs and occasional characteristic skin lesions. (biomedcentral.com)
  • Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. (exbio.cz)
  • CD30 positivity may also be observed in large cell transformation in MF, Hodgkin lymphoma, and other reactive disorders. (aad.org)
  • Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. (qxmd.com)
  • Brentuximab vedotin (Adcetris ® ), an anti-CD30 antibody conjugated to a potent microtubule inhibitor for the treatment of Hodgkin's lymphoma and anaplastic large cell lymphomas, is the only marketed ADC today. (springer.com)
  • Given that no other signs and symptoms of malignant lymphoma were present, the mediastinal tumor was surgically removed. (unipg.it)
  • TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient's own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target. (newsasiatoday.com)
  • CD30-positive cutaneous lymphoma: report of four cases with an emphasis on clinicopathological correlations. (investigacaoemdermatologia.com.br)
  • In this article, we present four different cases of CD30-positive T-cell lymphoma with cutaneous manifestations. (investigacaoemdermatologia.com.br)
  • Detects human CD30 ligand/TNFSF8 in direct ELISAs. (rndsystems.com)
  • Mouse myeloma cell line NS0-derived human CD30 Ligand/TNFSF8. (rndsystems.com)
  • CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. (rndsystems.com)
  • Human and mouse CD30 ligand cDNAs share 70% sequence homology. (rndsystems.com)
  • Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. (bdbiosciences.com)
  • The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
  • The ligand for CD30 is CD30L (CD153). (exbio.cz)
  • The ligand for CD30 is CD30 Ligand/TNFSF8 (CD153), a member of the TNF superfamily. (bio-techne.com)
  • Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. (genscript.com)
  • CD30 Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (wakehealth.edu)
  • This graph shows the total number of publications written about "CD30 Ligand" by people in this website by year, and whether "CD30 Ligand" was a major or minor topic of these publications. (wakehealth.edu)
  • Below are the most recent publications written about "CD30 Ligand" by people in Profiles. (wakehealth.edu)
  • In reactive conditions, CD30 receptor and ligand (CD30L, CD153) expression is normally seen on activated T-immunoblasts and B-immunoblasts. (aad.org)
  • Visualising an antibody-antigen interaction can be accomplished in a number of ways, mainly either of the following: Chromogenic immunohistochemistry (CIH), wherein an antibody is conjugated to an enzyme, such as peroxidase (the combination being termed immunoperoxidase), that can catalyse a colour-producing reaction. (wikipedia.org)
  • Depending on the method of fixation and tissue preservation, the sample may require additional steps to make the epitopes available for antibody binding, including deparaffinization and antigen retrieval. (wikipedia.org)
  • Depending on the tissue type and the method of antigen detection, endogenous biotin or enzymes may need to be blocked or quenched, respectively, prior to antibody staining. (wikipedia.org)
  • Quality control should as a minimum include a tissue known to express the antigen as a positive control and negative controls of tissue known not to express the antigen, as well as the test tissue probed in the same way with omission of the primary antibody (or better, absorption of the primary antibody). (wikipedia.org)
  • Primary antibodies are raised against an antigen of interest and are typically unconjugated (unlabeled), while secondary antibodies are raised against immunoglobulins of the primary antibody species. (wikipedia.org)
  • CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. (rndsystems.com)
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
  • AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. (pharmaceutical-technology.com)
  • Small-molecule inhibitors, antagonistic monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific antibodies or biologics (bsAbs) and chimeric antigen receptor-modified T cells (CAR-Ts) targeting Notch signaling components have been developed as investigational anti-cancer drugs ( 10 - 12 ). (spandidos-publications.com)
  • Moreover, the antibody is particularly reactive in tumors of glandular origin (e.g. sweat glands). (histoprime.com)
  • The antibody also detects some lymphoid neoplasms, especially CD30-positive large cell lymphomas. (histoprime.com)
  • A new monoclonal antibody to epithelial membrane antigen (EMA) - E29. (histoprime.com)
  • Compared with the reference 1+1 antibody, ABL602 did not induce the release of cytokines including interleukin-6 and tumor necrosis factor-α in the healthy donor-derived peripheral blood mononuclear cell. (bvsalud.org)
  • CAR has scFv derived from antibody, containing CD3ζ and costimulatory domain(s), making engineered CAR able to recognize specific tumor associated antigens. (cip.com.cn)
  • the endocytic pathway, and tumor cell growth arrest induced by antibody-toxin conjugates suggest therapeutic approaches that would selectively target tumors while limiting adverse drug effects in healthy cells. (gasyblog.com)
  • Antibody-drug conjugates (ADCs) combine the advantages of high targeting of antibody drugs and high activity of Payload in tumor tissues, providing better efficacy than traditional antibody-based therapeutic agents and demonstrating great clinical value. (huatengsci.com)
  • Background The use of bispecific Innate Cell Engagers (ICE®) has become a successful strategy for immune cell activation and killing of tumor cells through antibody-dependent cellular cytotoxicity (ADCC). (bmj.com)
  • Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 + Malignancies. (bmj.com)
  • The earliest study was conducted by Falini and his associates3 in Italy and Germany utilizing a CD30 antibody coupled to saporin for the treatment of four patients with advanced Hodgkin's disease. (atsbio.com)
  • In vivo studies with TNFSF9 knockout mice and with the agonistic anti-TNFRSF9 monoclonal antibody showed that TNFRSF9/TNFSF9 interaction keeps optimal CD8 T-cell mediated immune response against viral infections and tumors. (biolegend.com)
  • The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. (rndsystems.com)
  • CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. (rndsystems.com)
  • The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. (exbio.cz)
  • Modification with chimeric antigen receptors (CARs) endows T cells with tumor specific cytotoxicity and thus induce anti-tumor immunity against malignancies. (ijbs.com)
  • 2 Alternatively, as NK cells alone show short time clinical activity only, genetic modification with chimeric antigen receptors (CAR) has demonstrated improved clinical success in patients with CD19+ haematological disorders. (bmj.com)
  • Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
  • NK cell cytotoxic activation was assessed by calcein-release assays, degranulation, cytokine production, and specific CD19 positive target cell killing resolved over time using IncuCyte imaging system after co-culture of non-transduced NK cells plus CD16A/CD19-targeting ICE or anti-CD19 CAR-NK cells with CD19-positive or negative tumor target cells. (bmj.com)
  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. (bmj.com)
  • These initial results encouraged us to undertake preclinical investigations with immunotoxins directed against the B-cell restricted CD19 antigen for B-lymphoid tumors and against the CD38 molecule for multiple myeloma. (atsbio.com)
  • Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) were tested 20 times on one plate, respectively. (biomatik.com)
  • Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) were tested on 3 different plates, 8 replicates in each plate. (biomatik.com)
  • This assay has high sensitivity and excellent specificity for detection of Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8). (biomatik.com)
  • No significant cross-reactivity or interference between Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) and analogues was observed. (biomatik.com)
  • CD30 is a transmembrane glycoprotein receptor of the tumor necrosis factor receptor super family 8 (TNFRSF8), mediating its effects through a number of signaling pathways that produce a survival advantage to the cells on which the protein is overexpressed. (aad.org)
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. (lookformedical.com)
  • A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. (lookformedical.com)
  • Inactivation of tumor suppressor genes, whose products normally provide negative control of cell proliferation, contributes to malignant transformation in various cell types. (medscape.com)
  • Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. (wikidoc.org)
  • CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κB-inducing kinase. (bdbiosciences.com)
  • CD27 is a 50 kDa member of the tumor necrosis factor (TNF) receptor superfamily that includes CD40 and CD30. (thermofisher.com)
  • A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. (lookformedical.com)
  • CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. (exbio.cz)
  • OX40 is a T cell co-stimulatory molecule of the TNF receptor superfamily that coordinates with other co-stimulators (CD28, CD40, CD30, CD27 and 4-1BB) to manage the activation of the immune response. (genscript.com)
  • It is known to target tumor necrosis factor receptor superfamily member 8. (pharmakb.com)
  • TNFRSF9, also known as 4-1BB and CD137, is a member of the tumor necrosis factor receptor superfamily (TNFRSF). (biolegend.com)
  • High expression levels of CD27 appear to be dependent on proper ligation of antigen receptors. (thermofisher.com)
  • Ly6C high MC presented downregulated co-stimulatory receptors (CD2, GITR, and TIM1) which direct immune cell proliferation, and upregulated co-stimulatory ligands (LIGHT and SEMA4A) which trigger antigen priming and differentiation. (frontiersin.org)
  • Although antibodies show preferential avidity for specific epitopes, they may partially or weakly bind to sites on nonspecific proteins (also called reactive sites) that are similar to the cognate binding sites on the target antigen. (wikipedia.org)
  • A great amount of non-specific binding causes high background staining which will mask the detection of the target antigen. (wikipedia.org)
  • Even though clinical results are encouraging for both approaches, several major challenges have been identified, including: target antigen selection such as less tumor toxicity and antigen escape, T cell homing to the tumor, T cell infiltration into the tumor, T cell persistence, and local immunosuppression in the tumor microenvironment. (cip.com.cn)
  • Synthetic biology technologies have enabled flexible reprogramming of engineered T cells to overcome the aforementioned limitations, bringing new opportunities for improving their safety and effectiveness, but the choice of a suitable target antigen is still a key for success. (cip.com.cn)
  • In the following studies attributes of SAS1B are defined that support its candidacy like a tumor cell-specific target antigen, including tumor cell-surface convenience, immunogenicity, internalization of immune complexes into the endosomal-lysosomal system, and immunotoxin delivery resulting in tumor cell growth arrest = 4 experiments). (gasyblog.com)
  • Song et al identified a tumor suppressor gene that encodes the A-20 protein, which acts as an inhibitor to the NF-kappa-B pathway downstream from the tumor necrosis factor (TNF) receptor. (medscape.com)
  • CD30 protein solution (1mg/ml) containing 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, 10% glycerol and 1mM DTT. (angioproteomie.com)
  • [ 1 ] His prediction was subsequently supported by the cloning of the retinoblastoma tumor suppressor gene ( RB1 ) and by functional studies of the retinoblastoma protein, Rb. (medscape.com)
  • Like Rb protein, many of the proteins encoded by tumor suppressor genes act at specific points in the cell cycle. (medscape.com)
  • Lastly, SAS1B's normal restriction among normal healthy tissues to the pool of growing oocytes in the ovary provides a strategy for tumor selective focusing on in cancers that communicate this cell surface protein. (gasyblog.com)
  • Stimulation of CD30 leads signal mediation through tumor necrosis factor receptor-associated proteins (TRAF), thereby stimulating the nuclear factor-kappa B (NFkB) pathway and the mitogen-activated protein kinase (MAPK) pathways. (aad.org)
  • A poignant reminder here was the disastrous peripheral nerve damage experienced by women with breast cancer treated with a ricin A chain-based immunotoxin which unexpectedly also targeted nervous tissue.4 The most sensitive in vitro method for determining the selective cytotoxic potency of saporin-based immunotoxins is by measuring their ability to selectively inhibit protein synthesis in antigen-expressing cell lines in a dose-dependent manner. (atsbio.com)
  • CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. (rndsystems.com)
  • CD30 can act as a co-stimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30 + lymphomas. (rndsystems.com)
  • The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
  • CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. (exbio.cz)
  • In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. (exbio.cz)
  • The CD27 antigen is a lymphocyte-specific member of the tumor necrosis factor receptor (TNFR) super family, which also includes nerve growth factor receptor, CD30, CD40, CD95 (Fas), CD120a, CD120b, CD134 (OX 40), and CD137. (bdbiosciences.com)
  • A total of 27 ADC are currently undergoing clinical trials in both hematological malignancies and solid tumor indications. (springer.com)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
  • Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. (lookformedical.com)
  • Brentuximab vedotin represents a first-in-class ADC directed against CD30-positive malignancies. (biomedcentral.com)
  • Whilst there have been anti-tumor responses with ricin-based immunotoxins, particularly in hematological malignancies,2 their toxicity profile has limited their clinical usefulness and interest in their utility has consequently dropped away. (atsbio.com)
  • It involves the process of selectively identifying antigens (proteins) in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. (wikipedia.org)
  • Immunohistochemical staining is widely used in the diagnosis of abnormal cells such as those found in cancerous tumors. (wikipedia.org)
  • The tumor cells resemble immunoblasts or centroblasts, and, in many cases, sclerosis and fibrosis can be identified. (medscape.com)
  • Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4 + /CD8 + thymocytes that co-express CD45RO and IL-4 receptor. (rndsystems.com)
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)
  • It generates multi-specific antibodies to kill tumor cells and treat cancers through its ROCK platform technology. (pharmaceutical-technology.com)
  • Notch signaling cascades crosstalk with fibroblast growth factor and WNT signaling cascades in the tumor microenvironment to maintain cancer stem cells and remodel the tumor microenvironment. (spandidos-publications.com)
  • About 30% to 40% of PTCL, NOS, express markers of cytotoxic T-cells such as T-cell intracellular antigen-1 (TIA-1). (webpathology.com)
  • Expression of the activation marker CD30 may be seen in occasional tumor cells. (webpathology.com)
  • 1 T cells are engineered to express CARs through viral vectors, enabling them to recognize specific target antigens. (bdbiosciences.com)
  • The resultant activation of T cells is then exploited for tumor elimination. (bdbiosciences.com)
  • Patient PBMCs are collected by leukapheresis followed by enrichment approaches to isolate T cells while removing other cells such as B cells, monocytes, neutrophils, dendritic cells and contaminating tumor cells. (bdbiosciences.com)
  • The fourth generation of CAR-T design attempts to deliver cytokines to modulate the tumor microenvironment either by activating host effector T cells or hampering host suppressors and reinforcing memory T cells. (bdbiosciences.com)
  • Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
  • The tumour cells show abundant clear cytoplasm, large, rounded nuclei and prominent nucleoli. (testicularcancersociety.org)
  • There are scattered lymphocytes in the fibrous septa between nests of tumour cells. (testicularcancersociety.org)
  • Abundant glycogen granules are seen in the tumour cells, including intratubular component, confirmed by a PAS stain with diastase predigestion. (testicularcancersociety.org)
  • Immunohistochemistry shows no expression of EMA and CD30 antigens in the tumour cells. (testicularcancersociety.org)
  • PLAP and ckit are positive in the tumour cells. (testicularcancersociety.org)
  • The gene encodes a chimaeric antigen receptor (CAR) that targets leukaemia cells. (wikimili.com)
  • ABL602-mediated T-cell activation and tumor-killing activities were determined by measuring the expression of activation markers, cytokines, cytolytic proteins, and the proportion of dead cells. (bvsalud.org)
  • Together with CD3xTRP1 in the circulation being mainly unattached, this indicates that CD3+ T cells are generally not traffickers of CD3-bsAbs to the tumor. (bvsalud.org)
  • These ITs, BB10.dgA (CD2S), HRS3.dgA (CD30), and IRac.dgA (70 kDa), strongly inhibited the growth of L540Cy H‐RS cells in vitro. (elsevierpure.com)
  • This was at least in part due to the non‐homogeneous distribution of CD25, CD30 or IRac on the L540Cy H‐RS target cells and to the fact that sub‐populations deficient in one antigen nevertheless expressed appreciable levels of the other target antigens. (elsevierpure.com)
  • Analysis of 7 L540Cy sub‐lines re‐established ex vivo from mice that relapsed after having achieved complete remission (CR) after therapy with a single IT showed that the surviving tumor cells were antigen‐deficient variants which were resistant to the original IT, but which could be killed by ITs directed against other target antigens. (elsevierpure.com)
  • These changes can be inherited and are, therefore, found in every cell, but more often, they are somatically acquired and restricted to tumor cells. (medscape.com)
  • Due to their structure difference, TCR-T and CAR-T cells show different characteristics in signal activation and antigen recognition. (cip.com.cn)
  • In this article, we address structure and signal activation, target selection, affinity optimization, safety modification and gene editing strategies for engineered T cells, and also review the potential synthetic biological approaches and latest progress of engineered T cell therapy in the application of tumor immunotherapy. (cip.com.cn)
  • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. The New England Journal of Medicine , 2013 , 368 (16): 1509-1518. (cip.com.cn)
  • The majority of ALK+ ALCL tumor cells have been shown to express at least one T-cell specific marker. (biomedcentral.com)
  • In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. (exbio.cz)
  • Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. (exbio.cz)
  • In addition to the direct cytotoxic effect on tumour cells, dolastatins efficiently promoted antigen uptake and migration of tumour-resident DCs to tumour-draining lymph nodes. (biomedcentral.com)
  • Fourth, tumor cells expressing SAS1B can be killed by a SAS1B-directed immunotoxin that employs a pH sensitive linker arm and saporin payload. (gasyblog.com)
  • SAS1B is accessible within the surfaces of tumor cells SAS1B was recognized in permeabilized ASTL mRNA+ tumor cells throughout the cytoplasm and was concentrated in the perinuclear endoplasmic reticulum/Golgi region. (gasyblog.com)
  • In addition to this intracellular populace, SAS1B molecules were also imaged by staining within the surfaces of live cells recovered from both main uterine tumors and founded MMMT cell lines. (gasyblog.com)
  • Advances in our understanding on the interaction between the immune system and tumor cells have contributed to the rapid development of novel therapeutic strategies based on chimeric antigen receptor (CAR) or T cell receptor (TCR) modified T cells. (ijbs.com)
  • One is the ability to administer large numbers of highly selected cells with high avidity for tumor antigens that can recognize shared and patient-specific mutated (neo) antigens. (biomedcentral.com)
  • Successful TIL therapy starts with the identification, enrichment, stimulation, and expansion of potent tumor-reactive T cells. (biomedcentral.com)
  • Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. (exbio.cz)
  • Underlining the requirement of an intact host immune system for the full therapeutic benefit of dolastatins, the anti-tumour effect was far less pronounced in immune-compromised mice. (biomedcentral.com)
  • Ultimately, ADCs using dolastatins induce DC homing and activate cellular anti-tumour immune responses in patients. (biomedcentral.com)
  • The past decade has seen the discovery and development of novel treatments that harness the patient's immune system and prevent immune escape due to increased understanding of the tumor immune environment. (biomedcentral.com)
  • There is also a need for rational combinations beyond interleukin (IL)-2 and programmed death (PD)-1/ cytotoxic T-lymphocyte-associated antigen (CTLA)-4 immune checkpoint blockade and to combat exhaustion and restore costimulatory functions, e.g., with gene-engineered or pharmacologic agent-treated TILs. (biomedcentral.com)
  • Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. (bdbiosciences.com)
  • Meanwhile, the on-target/off-tumor toxicity caused by relative expression of target on normal tissues is another issue that should be reckoned. (ijbs.com)
  • Furthermore, the on-target/off-tumor toxicity can pose significant risks. (ijbs.com)
  • The development of such therapeutic molecules required robust preclinical investigations to determine their toxicity profiles in animals, the normal tissue-binding specificities, and to demonstrate their selective anti-tumor activity both in vitro and in vivo. (atsbio.com)
  • ANDERSON, A K, STROMNES I M, GREENBERG P D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies[J]. Cancer Cell , 2017 , 31 (3): 311-325. (cip.com.cn)
  • In addition to milk, these proteins are found in a number of normal epithelia as well as in tumors derived from them. (histoprime.com)
  • Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion . (wikidoc.org)
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • 1988). Coexpression of epithelial membrane antigen (EMA), Ki-1, and Interleukin-2 receptor by anaplastic large cell lymphomas. (histoprime.com)
  • Murine tumors displayed the phenotypic diversity observed in ALK+ ALCL patients, including CD4+ and CD8+ lymphomas. (biomedcentral.com)
  • absence/loss of pan B-cell and pan T-cell antigens), reactive cell population of other lineage, aberrant antigen expression, gene rearrangement studies, lineage infidelity, dual clones, and composite lymphomas. (aad.org)
  • BACKGROUND: CD3 bispecific antibodies (CD3-bsAbs) require binding of both a tumor-associated surface antigen and CD3 for their immunotherapeutic effect. (bvsalud.org)
  • This combination is expected to bring together the benefits of highly potent drugs on the one hand and selective binders of specific tumor antigens on the other hand. (springer.com)
  • In epithelial tumors, this marker is also strongly expressed. (histoprime.com)
  • Specifically, we found that the WNT signaling cell surface receptor ROR2 represented a robust and genuine marker of all ALK+ ALCL patient tumor samples. (biomedcentral.com)
  • CEA measurement is mainly used as a tumor marker to identify recurrences after surgical resection. (wikidoc.org)
  • CD30 acts as a costimulatory molecule in thymic negative selection. (exbio.cz)
  • Tumors metastatic to mediastinal lymph nodes represent the most common mediastinal lesions and must be differentiated from primary lesions. (allenpress.com)
  • For formalin-fixed paraffin-embedded tissues, antigen-retrieval is often necessary, and involves pre-treating the sections with heat or protease. (wikipedia.org)
  • This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. (lookformedical.com)
  • Studies with control bsAbs demonstrated that uptake of CD3xTRP1 in TRP1-positive tumors and CD3-rich tissues was primarily receptor-mediated. (bvsalud.org)
  • We further demonstrated rapid internalization of CD3xTRP1 in KPC3-TRP1 tumors (24 hours pi: 54.9%±2.3% internalized) and CD3-rich tissues (spleen, 24 hours pi: 79.7%±0.9% internalized). (bvsalud.org)
  • Murine MC are divided into three subsets based on surface expression of lymphocyte antigen 6 complex, locus C (Ly6C) ( 3 , 4 ). (frontiersin.org)
  • As ROR2 targeting approaches for other cancers are under development (including lung and ovarian tumors), our findings suggest that ALK+ ALCL cases with resistance to current therapies may also benefit from ROR2 targeting strategies. (biomedcentral.com)
  • While the majority of ALK+ ALCL tumors are CD4+ (approx. (biomedcentral.com)
  • IT cocktails were also superior as anti‐tumor agents in nude mice with solid L540Cy tumors. (elsevierpure.com)
  • Mediastinal tumors/lesions are frequently encountered in daily cytopathology practice. (allenpress.com)
  • To provide an updated review on the fine-needle aspiration cytology of mediastinal tumors/lesions, with an emphasis on diagnostic challenges. (allenpress.com)
  • Data were gathered from a PubMed search of peer-reviewed literature on mediastinal tumors. (allenpress.com)
  • Phase III clinical trials of Rova‑T for patients with small‑cell lung cancer and a phase III clinical trial of nirogacestat for patients with desmoid tumors are ongoing. (spandidos-publications.com)
  • In clinical practice, a key challenge for generating TIL products is the accessibility, quantity, and quality of tumor tissue in the era of neo-adjuvant therapy. (biomedcentral.com)
  • 1 Combination of adoptive NK cell therapy with ICE® molecules significantly improved tumor-targeting and has shown unprecedented clinical response rates in heavily pretreated cancer patients. (bmj.com)
  • Other compounds, such as CMC-544, SAR3419, CDX-011, PSMA-ADC, BT-062, and IMGN901 currently in clinical trials, targeting varied antigens and bearing different linker and drugs, contribute to the learning curve of ADC, as do the discontinued ADC. (springer.com)
  • Therefore, CAR has an ability to bind unprocessed tumor surface antigens without MHC processing, while TCR engages with both tumor intracellular and surface antigens embedded in MHC. (cip.com.cn)
  • In recent years, engineering T cell therapy has made great progress in tumor immunotherapy, which mainly includes T-cell receptor-engineered T cell (TCR-T) therapy and chimeric antigen receptor T cell (CAR-T) therapy. (cip.com.cn)
  • However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. (biomedcentral.com)
  • We evaluated in vivo tumor growth inhibitory activity in two mouse models bearing subcutaneously and orthotopically engrafted human AML. (bvsalud.org)
  • Sixty percent of cases express 1 or more T-cell antigens (CD3 + , CD43, or CD45RO). (medscape.com)
  • The antigen can also be detected in squamous cell carcinomas, even if the epithelium of origin (e.g. epidermis) itself is not reactive. (histoprime.com)
  • If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. (lookformedical.com)
  • METHODS: ABL602 candidates were compared in terms of binding activity, T-cell activation, and tumor-killing activities. (bvsalud.org)
  • Direct tumor-killing activity and T-cell activation in patient-derived AML blasts were also evaluated. (bvsalud.org)
  • Although the CD3 binding activity was attenuated compared with that of 1+1, ABL602 2+1 exhibited much stronger T-cell activation and potent tumor-killing activities in AML cell lines. (bvsalud.org)
  • Another important class of tumor suppressor genes involved in cell cycle control and in the generation of human cancers is the cyclin-dependent kinase (CDK) inhibitors. (medscape.com)
  • Neu is so named because it was derived from a rodent glioblastoma cell line, a type of neural tumor. (iiab.me)
  • Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. (bmj.com)